Related Experiment Video

Updated: Aug 15, 2026

Strategies for Assessing Autistic-Like Behaviors in Mice
07:38

Strategies for Assessing Autistic-Like Behaviors in Mice

Published on: September 20, 2024

BRIGHTLINE-1: When a Negative Trial Reveals Two Active Therapies

Adel Shahnam1, Mrinal M Gounder1

  • 1Memorial Sloan Kettering Cancer Center New York, NY United States.

Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|August 14, 2026
PubMed

Insights

Brigimadlin demonstrated biological activity in DDLPS, with a median PFS of 8.4 months and ORR of 22.3%. The BRIGHTLINE-1 trial

Area of Science:

  • Oncology
  • Pharmacology

Background:

  • The BRIGHTLINE-1 trial investigated brigimadlin for Dedifferentiated Liposarcoma (DDLPS).
  • Previous assumptions regarding control arm efficacy in DDLPS may have influenced trial outcomes.

Purpose of the Study:

  • To evaluate the efficacy and biological activity of brigimadlin in patients with DDLPS.
  • To assess p53 reactivation as a translational marker.

Main Methods:

  • Phase II clinical trial design.
  • Assessment of progression-free survival (PFS) and objective response rate (ORR).
  • Translational analysis for p53 pathway activity.

Main Results:

  • Brigimadlin exhibited median PFS of 8.4 months and ORR of 22.3%.
  • Evidence of p53 reactivation was observed, indicating biological engagement.
  • Doxorubicin, the control arm, exceeded retrospective expectations, setting a higher benchmark.

Conclusions:

  • Brigimadlin shows notable biological activity in DDLPS, despite the trial's headline outcome.
  • Flawed control arm assumptions may have contributed to the trial's 'negative' classification.
  • The study highlights the need for refined control arm considerations in DDLPS clinical trials.

More Related Videos

Assessment of Mouse Judgment Bias through an Olfactory Digging Task12:10

Assessment of Mouse Judgment Bias through an Olfactory Digging Task

Published on: March 4, 2022

Related Concept Videos

Blinding01:11

Blinding

Blinding is a commonly used method of not telling participants which treatment a subject is receiving. Blinding is a critical part of a randomized control trial or RCT. It reduces the bias that affects the results. In an RCT, blinding is used in the form of a placebo. A placebo effect occurs when untreated subjects falsely believe they have received the treatment and report improved symptoms. A placebo or a dummy treatment is administered to subjects to negate the bias caused by such an effect.
Blind Procedures02:07

Blind Procedures

Ideally, the people who observe and record the children’s behavior are unaware of who was assigned to the experimental or control group, in order to control for experimenter bias. Experimenter bias refers to the possibility that a researcher’s expectations might skew the results of the study. Remember, conducting an experiment requires a lot of planning, and the people involved in the research project have a vested interest in supporting their hypotheses. If the observers knew which child was...